Overview

Meaningful and Sustainable Solutions to Increase Postpartum Depression Screening and Treatment

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

Start Activity

Format

Interactive Practice Guide

Time to Complete

1.25 hr(s).

Release Date

March 14, 2025

Expires On

March 14, 2026

Postpartum depression (PPD) is one of the most common morbidities related to childbirth, yet it remains underdiagnosed and undertreated, with a mere 25% of patients ultimately receiving treatment. Untreated PPD can have dire consequences for mother, baby, and family, including suicide, which is the leading cause of death in the perinatal period. To address gaps in care, this educational activity has compiled educational resources and practical tools to help you improve guideline-recommended screening and management practices. It also includes downloadable slide decks and discussion guides to initiate meaningful conversations and improve interprofessional care within your team. Drive changes to positively impact care for your patients by conducting routine screening to recognize PPD earlier and reduce delays in initiating evidence-based treatment.

This activity is intended for OB/GYNs, maternal fetal medicine physicians, psychiatrists, APPs and nurses who manage patients with or at-risk of postpartum depression.

Postpartum depression (PPD) is one of the most common morbidities related to childbirth, affecting 13-19% of women. However, only 35% of women with PPD are identified in the clinic despite guideline recommendations calling for screening with a validated assessment tool at several time points in the perinatal period. Of patients identified with PPD, only 25.8% ultimately receive treatment, resulting in negative consequences for the mother, baby, and family. PPD has historically been treated with non-specific antidepressants, but there is limited evidence on the efficacy and safety of antidepressants for PPD, and their slow onset of action leads to suboptimal treatment outcomes. Advances in understanding of the pathophysiology of PPD have led to the recent approval of novel neurosteroid therapeutics for the treatment of PPD. Thus, there is a need to increase screening of perinatal women to improve outcomes and ensure therapeutic interventions are initiated earlier.

Upon completion of this activity, learners will be able to:
• Interpret and apply guideline-recommended strategies to increase screening for peripartum depression
• Interpret the most up-to-date clinical trial data surrounding novel neurosteroids for the treatment of postpartum depression (PPD)
• Model frameworks to reduce the median time to optimal and equitable treatment in women with PPD

This educational activity is presented in collaboration with the American College of Osteopathic Obstetricians and Gynecologists, Rush University Medical Center, and the Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Sage Therapeutics, Inc.

Melisa Lott, DO
Maternal Fetal Medicine Physician – Adjunct Faculty
Midwestern University – Chicago College of Osteopathic Medicine
Downers Grove, IL
Maternal Fetal Medicine Physician
Rush Copley Medical Center
Aurora, IL

Jessica Boudos, PA-C

Physician Assistant - Maternal Fetal Medicine

Advocate Aurora Health at Lutheran General Hospital

Park Ridge, IL

Kristina M. Deligiannidis, MD

Director, Women’s Behavioral Health, Zucker Hillside Hospital

Glen Oaks, NY

Professor of Psychiatry, Obstetrics and Gynecology and Molecular Medicine

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Hempstead, NY

Marianne Corrieri-Alaniz, BSN

Rush University Medical Center

Nurse Planner-Peer Reviewer

It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education (ICPE) to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.

The following financial relationships have been provided:

Melisa Lott, DO

Advisory Board Member: Natera, Inc.

Jessica Boudos, PA-C

No financial relationships to disclose.

Kristina M. Deligiannidis, MD

Research Grant: Gerbera Therapeutics, Premier Healthcare, Sage Therapeutics, Woebot Health

Consultant: Biogen, Brii Biosciences, Gerbera Therapeutics, GH Research, Neuroscience Software, Reunion Neuroscience, Sage Therapeutics

Marianne Corrieri-Alaniz, BSN

No financial relationships to disclose.

Staff members from Rush University Medical Center and the Office of Interprofessional Continuing Education, the American College of Osteopathic Obstetricians and Gynecologists, the Academy for Continued Healthcare Learning (ACHL), and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Rush University Medical Center, the American College of Osteopathic Obstetricians and Gynecologists, and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: SSRI/SNRI antidepressants not approved for PPD

To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The American College of Osteopathic Obstetricians and Gynecologists is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this Internet Enduring Material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Physician assistants (PAs) and nurse practitioners (NPs) may participate in this educational activity and earn a certificate of completion as AAPA and AANP accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Rush University Medical Center designates this Internet Enduring Material for a maximum of 1.25 ANCC contact hour(s).

By providing your ABIM Diplomate number and date of birth, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS each month.

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

The American College of Osteopathic Obstetricians and Gynecologists designates this program for a maximum of 1.25 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.

Laurie Novoryta
lnovoryta@achlcme.org

Overview

Meaningful and Sustainable Solutions to Increase Postpartum Depression Screening and Treatment

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Provider Information

Supporter Information

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities